Advances in the development of macrocyclic inhibitors of hepatitis C virus NS3-4A protease

Current Topics in Medicinal Chemistry

Volumn 10, Issue 14, 2010, Pages 1403-1422

  Avolio, Salvatore ^a   Summa, Vincenzo ^a  

^a IRBM   (Italy)

Author keywords

Antivirals; Clinical candidates; Covalent inhibitor; Hepatitis C virus (HCV); Macrocycle; NS3; Peptide; Protease inhibitor

Indexed keywords

ABT 450; BI 201335; BOCEPREVIR; CILUPREVIR; ITMN 191; MACROCYCLIC COMPOUND; N [[[6 (2 CARBOXY 2,3 DIHYDRO 1H ISOINDOL 4 YL) 2,2 DIMETHYLHEXYL]OXY]CARBONYL] 3 METHYLVALYL 4 HYDROXYPROLYL 1 AMINO N (CYCLOPROPYLSULFONYL) 2 ETHYLCYCLOPROPANECARBOXAMIDE LACTONE; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 4A; PEGINTERFERON ALPHA; PHX 1766; PROTEINASE INHIBITOR; RIBAVIRIN; TELAPREVIR; TMC 435350; UNCLASSIFIED DRUG; VBY 376;

ACUTE HEPATITIS; ARTICLE; CHRONIC LIVER DISEASE; CLINICAL TRIAL; DRUG STRUCTURE; ENZYME ACTIVE SITE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; CATALYTIC DOMAIN; CLINICAL TRIALS AS TOPIC; HEPACIVIRUS; HUMANS; INTERFERON ALFA-2A; MACROCYCLIC COMPOUNDS; POLYETHYLENE GLYCOLS; PROTEASE INHIBITORS; VIRAL NONSTRUCTURAL PROTEINS; VIRUS REPLICATION;

EID: 77955600915     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802610792232051     Document Type: Article

References (113)

1. Seeff, L. B. Natural history of chronic hepatitis C. Hepatology 2002, 36, S35-S46.
2. The Global Burden of Hepatitis C Working Group. Global burden of disease (GBD) for hepatitis C. J. Clin. Pharmacol., 2004, 44, 20-29.
3. Shepard, C. W.; Finelli, L.; Alter, M. J. Global epidemiology of hepatitis C virus infection. Lancet Infect. Dis., 2005, 5, 558-567.
4. Bartosch, B.; Thimme, R.; Blum, H. E.; Zoulim, F. Hepatitis C virus-induced hepatocarcinogenesis. J. Hepatol., 2009, 57, 810-820.
5. Brown Jr, R. S. Hepatitis C and liver transplantation. Nature, 2005, 436, 973-978.
6. Manns, M. P.; Wedemeyer, H.; Cornberg, M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut, 2006, 55, 1350-1359.
7. Feld, J. J.; Hoofnagle, J. H. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature, 2005, 436, 967-972.
8. Pang, P. S.; Planet, P. J.; Glenn, J. S. The evolution of the major hepatitis C genotypes correlates with clinical response to interferon therapy. PLoS One, 2009, 4(8), e6579.
9. Meier, V.; Ramadori, G. Hepatitis C virus virology and new treatment targets. Expert Rev. Anti Infect. Ther., 2009, 7, 329-350.
10. Choo, Q. L.; Kuo, G.; Weiner, A. J.; Overby, L. R.; Bradley, D. W.; Houghton, M. Isolation of a cDNA clone derived from a blood-borne Non-A, Non-B viral hepatitis genome. Science, 1989, 244, 359-362.
11. Simmonds, P.; Bukh, J.; Combet, C.; Deleage, G.; Enomoto, N.; Feinstone, S.; Halfon, P.; Inchauspe, G.; Kuiken, C.; Maertens, G.; Mizokami, M.; Murphy, D. G.; Okamoto, H.; Pawlotsky, J-M.; Penin, F.; Sablon, E.; Shin-I, T.; Stuyver, L. J.; Jiirgen Thiel, H.; Viazov, S.; Weiner, A. J.; Widell, A. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology, 2005, 42, 962-973.
12. Moradpour, D.; Penin, F.; Rice, C. M. Replication of hepatitis C virus. Nat. Rev. Microbiol., 2007, 5, 453-463.
13. Bartenschlager, R.; Ahlborn-Laake, L.; Mous, J.; Jacobsen, H. Nonstructural protein 3 of the hepatitis C virus encodes a serine-type proteinase required for cleavage at the NS3/4 and NS4/5 junctions. J. Virol., 1993, 67, 3835-3844.
14. Tomei, L.; Failla, C.; Santolini, E.; De Francesco, R.; La Monica, N. NS3 is a serine protease required for processing of hepatitis C virus polyprotein. J. Virol., 1993, 67, 4017-4026.
15. Gale, M., Jr.; Foy, E. M. Evasion of intracellular host defence by hepatitis C virus. Nature, 2005, 436, 939-945.
16. De Francesco, R.; Urbani, A.; Nardi, M. C.; Tomei, L.; Steinku-hler, C.; Tramontano, A. A zinc binding site in viral serine protei-nases. Biochemistry, 1996, 35, 13282-13287.
17. Failla, C.; Tomei, L.; De Francesco, R. Both NS3 and NS4A are required for proteolytic processing of hepatitis C virus nonstruc-tural proteins. J. Virol., 1994, 68, 3753-3760.
18. Love, R. A.; Parge, H. E.; Wickersham, J. A.; Hostomsky, Z.; Habuka, N.; Moomaw, E. W.; Adachi, T.; Hostomska, Z. The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site. Cell, 1996, 87, 331-342.
19. Kim, J. L.; Morgenstern, K. A.; Lin, C.; Fox, T.; Dwyer, M. D.; Landro, J. A.; Chambers, S. P.; Markland, W.; Lepre, C. A.; O'Malley, E. T.; Harbeson, S. L.; Rice, C. M.; Murcko, M. A.; Ca-ron, P. R.; Thomson, J. A. Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide. Cell, 1996, 87, 343-355.
20. Yan, Y.; Li, Y.; Munshi, S.; Sardana, V.; Cole, J. L.; Sardana, M.; Steinkuhler, C.; Tomei, L.; De Francesco, R.; Kuo, L. C.; Chen, Z. Complex of NS3 protease and NS4A peptide of BK strain hepatitis C virus: a 2.2 A resolution structure in a hexagonal crystal form. Protein Sci., 1998, 7, 837-847.
21. Barbato, G.; Cicero, D. O.; Nardi, M. C.; Steinkuhler, C.; Cortese, R.; De Francesco, R.; Bazzo, R. The solution structure of the N-terminal proteinase domain of the hepatitis C virus (HCV) NS3 protein provides new insights into its activation and catalytic mechanism. J. Mol. Biol., 1999, 289, 371-384.
22. LaPlante, S. R.; Cameron, D. R.; Aubry, N.; Lefebvre, S.; Kukolj, G.; Maurice, R.; Thibeault, D.; Lamarre, D.; Llinas-Brunet, M. Solution structure of substrate-based ligands when bound to hepatitis C virus NS3 protease domain. J. Biol. Chem., 1999, 274, 18618-18624.
23. Nature Review Editorial. Protease inhibitors show promise against HCV. Nat. Rev. Drug Disc., 2009, 8, 1.
24. Asselah, T.; Benhamou, Y.; Marcellin, P. Protease and polymerase inhibitors for the treatment of hepatitis C. Liver Int., 2009, 29, 57-67.
25. Lamarre, D.; Anderson, P. C.; Bailey, M.; Beaulieu, P.; Bolger, G.; Bonneau, P.; Bos, M.; Cameron, D.; Cartier, M.; Cordingley, M. G.; Faucher, A.-M.; Goudreau, N.; Kawai, S. H.; Kukolj, G.; La-gace, L.; LaPlante, S. R.; Narjes, H.; Poupart, M.-A.; Rancourt, J.; Sentjens, R. E.; St George, R.; Simoneau, B.; Steinmann, G.; Thi-beault, D.; Tsantrizos, Y. S.; Weldon, S. M.; Yong, C.-L.; Llinas-Brunet, M. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature, 2003, 426, 186-189.
26. Hinrichsen, H; Benhamou, Y.; Wedemeyer, H.; Reiser, M.; Sent-jens, R. E.; Calleja, J. L.; Forns, X.; Erhardt, A.; Cronlein, J.; Chaves, R. L.; Yong, C.-L.; Nehmiz, G.; Steinmann, G., G. Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. Gastroenterology, 2004, 727, 1347-1355.
27. Reiser, M.; Hinrichsen, H.; Benhamou, Y.; Reesink, H. W.; We-demeyer, H.; Avendano, C.; Riba, N.; Yong, C.-L.; Nehmiz, G.; Steinmann, G. G. Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C. Hepatology, 2005, 47(4), 832-835.
28. For a definition of Ki and discussions, see: Morrison, J. F.; Walsh, C. T. The behaviour and significance of slow-binding enzyme inhibitors. In Advances in Enzymology and Related Areas of Molecular Biology, Meister, A., Ed.; John Wiley & Sons, Inc., Hoboken, NJ, 1988; Vol 67, pp 201-301.
29. The Schechter and Berger nomenclature is used to designate the inhibitor residues (e.g P4, P3, P2, P1, P1') that bind to the corresponding protease subsites (S4, S3, S2, S1, S1'). The scissile bond in the natural substrate resides between the P1 and P1' residues. Schechter, I.; Berger, A. On the size of the active site in proteases. I. Papain. Biochem. Biophys. Res. Commun., 1967, 27, 157-162.
30. Lin, C.; Kwong, A. D.; Perni, R. B. Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease. Infect. Disord. Drug Targets, 2006, 6, 3-16.
31. Lin, K.; Perni, R. B.; Kwong, A. D.; Lin, C. VX-950, a novel hepatitis C virus (HCV) NS3-4A protease inhibitor, exhibits potent antiviral activities in HCV replicon cells. Antimicrob. Agents Che-mother., 2006, 50, 1813-1822.
32. McHutchison, J. G.; Everson, G. T.; Gordon, S. C.; Jacobson, I. M.; Sulkowski, M.; Kauffman, R.; McNair, L.; Alam, J.; Muir, A. J. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N. Engl. J. Med., 2009, 360, 1827-1838.
33. Hezode, C.; Forestier, N.; Dusheiko, G.; Ferenci, P.; Pol, S.; Goe-ser, T.; Bronowicki, J.-P.; Bourliere, M.; Gharakhanian, S.; Bengts-son, L.; McNair, L.; George, S.; Kieffer, T.; Kwong, A.; Kauffman, R. S.; Alam, J.; Pawlotsky, J.-M.; Zeuzem, S. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N. Engl. J. Med., 2009, 360, 1839-1850.
34. Vertex homepage: http://investors.vrtx.com/releasedetail.cfm?ReleaseID=379752. Telaprevir data presented at EASL show unprecedented SVR rates in HCV treatment-failure patients in PROVE 3 study [Accessed September 15, 2009].
35. Venkatraman, S.; Bogen, S. L.; Arasappan, A.; Bennet, F.; Chen, K.; Jao, E.; Liu, Y.-T.; Lovey, R.; Hendrata, S.; Huang, Y.; Pan, W.; Parekh, T.; Pinto, P.; Popov, V.; Pike, R.; Ruan, S.; Santha-nam, B.; Vibulbhan, B.; Wu, W.; Yang, W.; Kong, J.; Liang, X.; Wong, J.; Liu, R.; Butkiewicz, N.; Chase, R.; Hart, A.; Agrawal, S.; Ingravallo, P.; Pichardo, J.; Kong, R.; Baroudy, B.; Malcom, B.; Guo, Z.; Prongay, A.; Madison, V.; Broske, L.; Cui, X.; Cheng, K.-C.; Hsieh, Y.; Brisson, J.-M.; Prelusky D.; Korfmacher, W.; White, R.; Bogdanowich-Knipp, S.; Pavlovsky, A.; Bradley, P.; Saksena, A. K.; Ganguly, A.; Piwinski, J.; Girijavallabhan, V.; Njoroge, F. G. Discovery of (1R,5S)-N-[3-Amino-1-(cyclobutylmethyl)- 2,3-dioxopropyl]-3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl] amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0] hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavailable hepatitis C virus NS3 protease inhibitor: a potential therapeutic agent for the treatment of Hepatitis C infection. J. Med. Chem., 2006, 49, 6074-6086.
36. Njoroge, F. G.; Chen, K. X.; Shih, N.-Y.; Piwinski, J. J. Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection. Acc. Chem. Res., 2008, 47, 50-59.
37. Kwo, P.; Lawitz, E.; McCone, J.; Schiff, E.; Vierling, J.; Pound, D.; Davis, M.; Galati, J.; Gordon, S.; Ravendhran, N.; Rossaro, L.; Anderson, F.; Jacobson, I.; Rubin, R.; Koury, K.; Brass, C.; Chaudhri, E.; Albrecht, J. HCV Sprint-1 final results: SVR 24 from a phase 2 study of Boceprevir plus Pegintron™ (peginterferon alfa-2B)/ribavirin in treatment-naive subjects with genotype-1 chronic hepatitis C. J. Hepatol., 2009, 50, A4, S4.
38. Schering-Plough homepage. Schering-Plough completes enrollment of Boceprevir registration studies in treatment-naive and treatment-experienced HCV patients. http://www.schering-plough.com/news/news_article.aspx?reqid=1248621 [Accessed September 15, 2009].
39. Forestier, N.; Larrey, D.; Marcellin, P.; Benhamou, Y.; Guyader, D.; Bradford, W.; Porter, S.; Patat, A.; Rouzier, R.; Zeuzem, S. Antiviral activity and safety of ITMN-191 in combination with pegin-terferon alfa-2A and ribavirin in patients with chronic hepatitis C virus (HCV). J. Hepatol., 2009, 50, A85, S35.
40. InterMune homepage: http://phx.corporate-ir.net/phoenix.zhtml?c=100067&p=irol-newsArticle&ID=1280404&highlight= Inter-Mune reports presentation of triple combination study of ITMN-191 at European association for the study of the liver (EASL). Accessed September 15, 2009.
41. Manns, M.; Reesink, H.; Moreno, C.; Berg, T.; Benhamous, Y.; Horsmans, Y.; Dusheiko, G.; Flisiak, R.; Meyvisch, P.; Lenz, O.; Sekar, V.; Van't Klooster, G.; Simmen, K.; Verloes, R. Opera-1 trial: interim analysis of safety and antiviral activity of TMC435 in treatment-naive genotype 1 HCV patients. J. Hepatol., 2009, 50, S7.
42. Tibotec homepage. New data on Tibotec investigational hepatitic C compounds being presented at EASL. http://www.tibotec.com/news/detail.jhtml?action=view&itemname=news_60 [Accessed September 15, 2009].
43. Wright, D. H.; Miller, J. L.; Verlinden, I.; Cilissen, C.; Valentine, J.; Sun, P.; De Smet, M.; de Hoon, J.; Depre, M.; Cavens, L.; Cho-dakewitz, J.; Wagner, J. A. Safety, tolerability, and pharmacoki-netic data following single- and multiple-dose administration of MK-7009, a hepatitis C virus non-structural 3/4a protease inhibitor, to healthy male subjects. Hepatology, 2008, 48, A1910, 1165A.
44. Merck homepage. Merck announces iInterim phase IIa study results of MK-7009, an investigational oral hepatitis C virus protease inhibitor, in patients with chronic hepatitis C. http://www.merck.com/newsroom/press_releases/research_and_development/2009_0423.html [Accessed September 15, 2009].
45. Seiwert, S. D.; Andrews, S. W.; Jiang, Y.; Serebryany, V.; Tan, H.; Kossen, K.; Rajagopalan, P. T. R.; Misialek, S.; Stevens, S. K.; Stoycheva, A.; Hong, J.; Lim, S. R.; Qin, X.; Rieger, R.; Con-droski, K. R.; Zhang, H.; Do, M. G.; Lemieux, C.; Hingorani, G. P.; Hartley, D. P.; Josey, J. A.; Pan, L.; Beigelman, L.; Blatt, L. M. Preclinical characteristics of the hepatitis C virus NS3/4A protease inhibitor ITMN-191 (R7227). Antimicrob. Agents Chemother., 2008, 52, 4432-4441.
46. Rajagopalan, R.; Misialek, S.; Stevens, S. K.; Myszka, D. G.; Brandhuber, B. J.; Ballard, J. A.; Andrews, S. W.; Seiwert, S. D.; Kossen, K. Inhibition and binding kinetics of the hepatitis C virus NS3 protease inhibitor ITMN-191 reveals tight binding and slow dissociative behavior. Biochemistry, 2009, 48, 2559-2568.
47. Raboisson, P.; De Kock, H.; Rosenquist, A.; Nilsson, M.; Salva-dor-Oden, L.; Lin, T.; Roue, N.; Ivanov, V.; Wahling, H.; Wick-strom, K.; Hamelink, E.; Edlung, M.; Vrang, L.; Vendeville, S.; Van de Vreken, W. V.; McGowan, D.; Tahri, A.; Hu, L.; Boutton, C.; Lenz, O.; Delouvroy, F.; Pille, G.; Surleraux, D.; Wigerinck, P.; Samuelsson, B.; Simmen, K. Structure-activity relationship study on a novel series of cyclopentane-containing macrocyclic inhibitors of the hepatitis C virus NS3/4A protease leading to the discovery of TMC435350. Bioorg. Med. Chem. Lett., 2008, 78, 4853-4858.
48. Lin, T.-I.; Lenz, O.; Fanning, G.; Verbinnen, T.; Delouvroy, F.; Scholliers, A.; Vermeiren, K.; Rosenquist, A.; Edlund, M.; Sa-muelsson, B.; Vrang, L.; de Kock, H.; Wigerinck, P.; Raboisson, P.; Simmen, K. In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor. Antimi-crob. Agents Chemother., 2009, 53, 1377-1385.
49. Kukolj, G.; Benhamou, Y.; Manns, M. P.; Bourliere, M.; Pol, S.; Schuchmann, M.; Cartier, M.; Huang, D.; Lagace, L.; Steinmann, G.; Stern, J. O. BI 201335, A potent HCV NS3 protease inhibitor, in treatment-naive and -experienced chronic HCV genotype-1 infection: genotypic and phenotypic analysis of the NS3 protease domain. J. Hepatol., 2009, 50, A954, S347.
50. Clinical trials homepage: http://clinicaltrials.gov/ct2/show/NCT00774397?term=bi+201335&rank=1. Antiviral effect and safety of BI201335 +PegIFN/RBV in HCV-GT1. [Accessed September 15, 2009].
51. Phenomix homepage. Phenomix initiates phase 1a clinical trial of hepatitis C protease inhibitor PHX1766. http://www.phenomixcorp.com/news-08-10-28.asp [Accessed September 15, 2009].
52. Enanta homepage. Abbott and Enanta initiate phase 1 clinical trial on ABT-450 HCV protease inhibitor. http://www.enanta.com/pr_021809.html [Accessed September 15, 2009].
53. Virobay homepage. Hepatitis C protease inhibitors: VBY-376 and VBY-106. http://www.virobayinc.com/hepatitis-c-protease-inhibitors.php [Accessed September 15, 2009].
54. Steinkiihler, C.; Koch, U.; Narjes, F.; Matassa, V. G. Hepatitis C virus protease inhibitors: current progress and future challenges. Curr. Med. Chem., 2001, 8, 919-932.
55. De Francesco, R.; Tomei, L.; Altamura, S.; Summa, V.; Migliac-cio, G. Approaching a new era for hepatitis C virus therapy: inhibitors of the NS3-4A serine protease and the NS5B RNA-dependent RNA polymerase. Antivir. Res,. 2003, 58, 1-16.
56. McPhee, F.; Yeung, K.-S.; Good, A. C.; Meanwell, N. A. Hepatitis C virus NS3 serine protease as a drug discovery target. Drugs Future, 2003, 28, 465-488.
57. Chen, S. H.; Tan, S. L. Discovery of small-molecule inhibitors of HCV NS3-4A protease as potential therapeutic agents against HCV infection. Curr. Med. Chem., 2005, 72, 2317-2342.
58. Goudreau, N.; Llinas-Brunet, M. The therapeutic potential of NS3 protease inhibitors in HCV infection. Expert Opin. Investig. Drugs, 2005, 74, 1129-1144.
59. De Francesco, R.; Carfi, A. Advances in the development of new therapeutic agents targeting the NS3-4A serine protease or the NS5B RNA-dependent RNA polymerase of the hepatitis C virus. Adv. DrugDeliv. Rev., 2007, 59, 1242-1262.
60. Ronn, R.; Sandstrom, A. New developments in the discovery of agents to treat hepatitis C. Curr. Top. Med. Chem., 2008, 8, 533-562.
61. Kwong, A. D.; McNair, L.; Jacobson, I.; George, S. Recent progress in the development of selected hepatitis C virus NS3-4A protease and NS5B polymerase inhibitors. Curr. Opin. Pharmacol., 2008, 8, 522-531.
62. Steinkuhler, C.; Biasol, G.; Brunetti, M.; Urbani, A.; Koch, U.; Cortese, R.; Pessi, A.; De Francesco, R. Product inhibition of the hepatitis C virus NS3 protease. Biochemistry, 1998, 37, 8899-8905.
63. Ingallinella, P.; Altamura, S.; Bianchi, E.; Taliani, M.; Ingenito, R.; Cortese, R.; De Francesco, R.; Steinkuhler, C.; Pessi, A. Potent peptide inhibitors of human hepatitis C virus NS3 protease are obtained by optimizing the cleavage products. Biochemistry, 1998, 37, 8906-8914.
64. Llinas-Brunet, M.; Bailey, M.; Fazal, G.; Goulet, S.; Halmos, T.; Laplante, S.; Maurice, R.; Poirier, M.; Poupart, M.-A.; Thibeault, D.; Wernic, D.; Lamarre, D. Peptide-based inhibitors of the hepatitis C virus serine protease. Bioorg. Med. Chem. Lett., 1998, 8, 1713-1718.
65. Llinas-Brunet, M.; Bailey, M.; Fazal, G.; Ghiro, E.; Gorys, V.; Goulet, S.; Halmos, T.; Maurice, R.; Poirier, M.; Poupart, M.-A.; Rancourt, J.; Thibeault, D.; Wernic, D.; Lamarre, D. Highly potent and selective peptide-based inhibitors of the hepatitis C virus serine protease: towards smaller inhibitors. Bioorg. Med. Chem. Lett., 2000, 70, 2267-2270.
66. Cicero, D. O.; Barbato, G.; Koch, U.; Ingallinella, P.; Bianchi, E.; Nardi, M. C.; Steinkuhler, C.; Cortese, R.; Matassa, V.; De Francesco, R.; Pessi, A.; Bazzo, R. Structural characterization of optimized product inhibitors with the W-terminal proteinase domain of the hepatitis C virus (HCV) NS3 protein by NMR and modelling studies. J. Mol. Biol., 1999, 289, 385-396.
67. LaPlante, S. R.; Aubry, N.; Bonneau, P. R.; Kukolj, G.; Lamarre, D.; Lefebvre, S.; Li, H.; Llinas-Brunet, M.; Plouffe, C.; Cameron, D. R. NMR line-broadening and transferred NOESY as a medicinal chemistry tool for studying inhibitors of the hepatitis C virus NS3 protease domain. Bioorg. Med. Chem. Lett., 2000, 10, 2271-2274.
68. Gallo, M.; Pennestri, M.; Bottomley, M. J.; Barbato, G.; Eliseo, T.; Paci, M.; Narjes, F.; De Francesco, R.; Summa, V.; Koch, U.; Bazzo, R.; Cicero, D. O. Binding of a noncovalent inhibitor exploiting the S' region stabilizes the hepatitis C virus NS3 protease conformation in the absence of cofactor. J. Mol. Biol., 2009, 385, 1142-1155.
69. Grieco, P.; Cai, M.; Liu, L.; Mayorov, A.; Chandler, K.; Trivedi, D.; Lin, G.; Campiglia, P.; Novellino, E.; Hruby, V. J. Design and microwave-assisted synthesis of novel macrocyclic peptides active at melanocortin receptors: discovery of potent and selective hMC5R receptor antagonists. J. Med. Chem., 2008, 51, 2701-2707.
70. Marsault, E.; Hoveyda, H. R.; Peterson, M. L.; Saint-Louis, C.; Landry, A.; Vezina, M.; Ouellet, L.; Wang, Z.; Ramaseshan, M.; Beaubien, S.; Benakli, K.; Beauchemin, S.; Deziel, R.; Peeters, T.; Fraser, G. L. Discovery of a new class of macrocyclic antagonists to the human motilin receptor. J. Med. Chem., 2006, 49, 7190-7197.
71. Tyndall, J. D.; Fairlie, D. P. Macrocyles mimic the extended pep-tide conformations recognized by aspartic, serine, cysteine, and metallo proteases. Curr. Med. Chem., 2001, 8, 893-907.
72. Li, P.; Roller, P. P. Cyclization strategies in peptide derived drug design. Curr. Top. Med. Chem., 2002, 2, 325-341.
73. Li, P.; Roller, P. P.; Xu, J. Current synthetic approaches to peptide and peptidomimetic cyclization. Curr. Org. Chem., 2002, 6, 411-440.
74. Venkatraman, S.; Njoroge, F. G. Macrocyclic inhibitors of HCV NS3-4A protease: design and structure activity relationship. Curr. Top. Med. Chem., 2007, 7, 1290-1301.
75. Venkatraman, S.; Njoroge, F. G. Macrocyclic inhibitors of HCV NS3 protease. Expert Opin. Ther. Patents, 2009, 19, 1-27.
76. Marchetti, A.; Ontoria, J. M.; Matassa, V. G. Synthesis of two novel cyclic biphenyl ether analogs of an inhibitor of HCV NS3 protease. Synlett, 1999, S1, 1000-1002.
77. Rich, D. H. Effect of hydrophobic collapse on enzyme-inhibitor interactions. Implications for the design of peptidomimetic. In: Perspectives in Medicinal Chemistry; Testa, B.; Kyburz, E.; Fuhrer, W.; Giger, R., Eds.; Verlag Helvetica Chimica Acta: Basel, 1993, pp 15-25.
78. Venkatraman, S.; Njoroge, F. G.; Girihavallabhan, V. M.; Madison, V. S.; Yao, N. H.; Prongay, A. J.; Butkiewicz, N.; Pichardo, J. Design and synthesis of depeptized macrocyclic inhibitors of hepatitis C NS3-4A protease using structure-based drug design. J. Med. Chem., 2005, 48, 5088-5091.
79. Tsantrizos, Y. S.; Bolger, G.; Bonneau, P.; Cameron, D. R.; Gou-dreau, N.; Kukolj, G.; LaPlante, S. R.; Llinas-Brunet, M.; Nar, H.; Lamarre, D. Macrocyclic inhibitors of the NS3 protease as potential therapeutic agents of hepatitis C virus infections. Angew. Chem., Int. Ed, 2003, 42, 1356-1360.
80. Yao, N.; Reichert, P.; Taremi, S. S.; Prosise, W. W.; Weber, P. C. Molecular views of viral polyprotein processing revealed by the crystal structure of the hepatitis C virus bifunctional proteasehelicase. Structure, 1999, 7, 1353-1363.
81. Liverton, N. J.; Holloway, M. K.; McCauley, J. A.; Rudd, M. T.; Butcher, J. W.; Carroll, S. S.; DiMuzio, J.; Fandozzi, C.; Gilbert, K. F.; Mao, S.-S.; McIntyre, C. J.; Nguyen, K. T.; Romano, J. J.; Stahlhut, M.; Wan, B.-L.; Olsen, D. B.; Vacca, J. P. Molecular modeling based approach to potent P2-P4 macrocyclic inhibitors of hepatitis C NS3/4A protease. J. Am. Chem. Soc., 2008, 130, 4607-4609.
82. Activities (Ki) against recombinant genotype 1b NS3 protease were determined using a time resolved fluorescence assay as reported in: Mao, S.-S.; DiMuzio, J.; McHale, C.; Burlein, C.; Olsen, D. B.; Carroll, S. S. A time-resolved, internally quenched fluorescence assay to characterize inhibition of hepatitis C virus nonstructural protein 3-4A protease at low enzyme concentrations. Anal. Biochem., 2008, 373, 1-8.
83. Inhibition of subgenomic HCV RNA replication was measured in HUH-7 cells using modifications of the procedure described by Bartenschlager as reported in: Migliaccio, G.; Tomassini, J. E.; Carroll, S. S.; Tomei, L.; Altamura, S.; Bhat, B.; Bartholomew, L.; Bosserman, M. R.; Ceccacci, A.; Colwell, L. F.; Cortese, R.; De Francesco, R.; Eldrup, A. B.; Getty, K. L.; Hou, X. S.; LaFemina, R. L.; Ludmerer, S. W.; MacCoss, M.; McMasters, D. R.; Stahlhut, M. W.; Olsen, D. B.; Hazuda, D. J.; Flores, O. A. Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro. J. Biol. Chem., 2003, 278, 49164-49170; EC50 values are reported generally in the presence of 10% Fetal Calf Serum (FCS) and in the more physiological conditions represented be the use of 50% Normal Human Serum (NHS) to assess the impact of protein binding.
84. Lohmann, V.; Korner, F.; Koch, J. O.; Herian, U.; Theilmann, L.; Bartenschlager, R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science, 1999, 285, 110-113.
85. Ronn, R.; Gossas, T.; Sabnis, Y. A.; Daoud, H.; Akerblom, E.; Danielson, U. H.; Sandstrom, A. Evaluation of a diverse set of potential P1 carboxylic acid bioisosteres in hepatitis C virus NS3 protease inhibitors. Bioorg. Med. Chem., 2007, 15, 4057-4068.
86. Ludmerer, S.; Graham, D.; Handt, L.; Fandozzi, C.; Burlein, C.; Liverton, N. J.; McCauley, J.; Vacca, J.; Hazuda, D.; Carroll, S.; Olsen, D. Evaluation of MK-7009, a novel macrocyclic inhibitor of NS3/4A protease, in the chimpanzee model of chronic hepatitis C virus infection. Antivir. Res., 2008, 78, A23.
87. McCauley, J. A.; Rudd, M. T.; McIntyre, C. J.; Nguyen, K. T.; Romano, J. J.; Butcher, J. W.; Holloway, M. K.; Wan, B.-L.; Carroll, S. S.; DiMuzio, J. M.; Graham, D. J.; Ludmerer, S. W.; Mao, S.-S.; Stahlhut, M.; Fandozzi, C.; Trainor, N.; Olsen, D. B.; Vacca, J. P.; Liverton, N. J. Discovery of MK-7009: a novel mac-rocyclic HCV NS3/4A protease inhibitor. Abstracts of Papers, 235th ACS National Meeting, New Orleans, LA, United States, 2008, April 6-10, American Chemical Society: Washington, DC, 2008; MEDI-018.
88. Manns, M. P.; Gane, E.; Rodriguez-Torres, M.; Stoehr, A.; Yeh, C.-T.; Wiedmann, R. T.; Hwang, P. M.; Quirk, E.; Silber, J.; Lee, A. W. MK-7009 significantly improves rapid viral response (RVRr) in combination with pegylated interferon alfa-2a and ri-bavirin in patients with chronic hepatitis C (CHC) genotype 1 infection. J. Hepatol., 2009, 50, A1056, S384.
89. Harper, S.; Ferrara, M.; Crescenzi, B.; Pompei, M.; Palumbi, M.; DiMuzio, J.; Donghi, M.; Fiore, F.; Koch, U.; Liverton, N. J.; Pesci, S.; Petrocchi, A.; Rowley, M.; Summa, V.; Gardelli, C. Inhibitors of the hepatitis C virus NS3 protease with basic amine functionality at the P3-amino acid N-terminus: discovery and optimisation of a new series of P2-P4 macrocycles. J. Med. Chem., 52, 4820-4837.
90. Di Francesco, M. E.; Dessole, G.; Nizi, E.; Pace, P.; Koch, U.; Fiore, F.; Pesci, S.; Di Muzio, J.; Monteagudo, E.; Rowley, M.; Summa, V. Novel macrocyclic inhibitors of hepatitis C NS3/4A protease featuring a 2-amino-1,3-thiazole as a P4 carbamate replacement. J. Med. Chem., 2009, 52 (22),7014-7028.
91. Nizi, E.; Koch, U.; Ponzi, S.; Matassa, V. G.; Gardelli, C. Capped dipeptide a-ketoacid inhibitors of the HCV NS3 protease. Bioorg. Med. Chem. Lett., 2002, 12, 3325-3328.
92. Sani, M.; Volonterio, A.; Zanda, M. The trifluoroethylamine function as peptide bond replacement. ChemMedChem, 2007, 2, 1693-1700.
93. Black, W. C.; Bayly, C. I.; Davis, D. E.; Desmarias, S.; Falgueyret, J.-P.; Leger, S.; Li, C. S.; Masse, F.; McKay, D. J.; Palmer, J. T.; Percival, M. D.; Robichaud, J.; Tsou, N.; Zamboni, R. Trifluoroethylamines as amide isosteres in inhibitors of Cathepsin K. Bioorg. Med. Chem. Lett., 2005, 15, 4741-4744.
94. Reviewed in Patani, G. A.; LaVoie, E. J. Bioisosterism: a rational approach in drug design. Chem. Rev., 1996, 96, 3147-3176.
95. Thompson, S.K.; Eppley, A. M.; Frazee, J. S.; Darcy, M. G.; Lum, R.T.; Tomaszek, T. A. Jr.; Ivanoff, L. A.; Morris, J. F.; Sternberg, E. J.; Lambert, D. M.; Fernandez, A.V.; Petteway S. R. Jr.; Meek, T. D.; Metcalf, B. W.; Gleason, J. G. Synthesis and antiviral activity of a novel class of HIV-1 protease inhibitors containing a het-erocyclic P1'-P2' amide bond isostere. Bioorg. Med. Chem. Lett., 1994, 4, 2441-2446.
96. Bartels, D. J.; Zhou, Y.; Zhang, E. Z.; Marcial, M.; Byrn, R. A.; Pfeiffer, T.; Tigges, A. M.; Adiwijaya, B. S.; Lin, C.; Kwong, A.; Kieffer, T. L. Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3-4A protease inhibitors in treatment-naive subjects. J. Infect. Dis., 2008, 198(6), 800-807.
97. Pompei, M.; Di Francesco, M. E.; Koch, U.; Liverton, N. J.; Summa, V. Bioorg. Med. Chem. Lett., 2009, 19, 2574-2578.
98. Chen, X.; Wang, W. The use of bioisosteric groups in lead optimization. Annu. Rep. Med. Chem., 2003, 38, 333-346.
99. Chaudhary, K.; Fleury, M.; Kim, C. U.; McMurtrie, D. J.; Sheng, X. C. Preparation of tripeptides bearing a cyclopropyl moiety and phosphorous groups as antiviral compounds. WO Patent Pub. 2006/020276.
100. Casarez, A.; Chaudhary, K.; Cho, A.; Clarke, M.; Doerffler, E.; Fardis, M.; Kim, C. U.; Pyun, H.; Sheng, X. C.; Wang, J. Cyclopropylphosphinic acids, conjugated with dipeptide 4-quinolinol ethers as antiviral agents for treatment of hepatitis C. WO Patent Pub. 2008/005565.
101. Avolio, S.; Robertson, K.; Martin Hernando, J. I.; Di Muzio, J.; Summa, V. Inhibitors of hepatitis C virus NS3/4A: a-Ketoamide based macrocyclic inhibitors. Bioorg. Med. Chem. Lett., 2009, 19, 2295-2298.
102. Raboisson, P.; Lin, T.-I.; de Kock, H.; Vendeville, S.; Van de Vreken, W.; McGowan, D.; Tahri, A.; Hu, L.; Lenz, O.; Delouvroy, F.; Surleraux, D.; Wigerinck, P.; Nilsson, M.; Rosenquist, A; Sam-uelsson, B.; Simmen, K. Discovery of novel potent and selective dipeptide hepatitis C virus NS3/4A serine protease inhibitors. Bioorg. Med. Chem. Lett., 2008, 18, 5095-5100.
103. Vendeville, S.; Nilsson, M.; de Kock, H.; Lin, T.-I.; Antonov, D.; Classon, B.; Ayesa, S.; Ivanov, V.; Johansson, P.-O.; Kahnberg, P.; Eneroth, A.; Wikstrom, K.; Vrang, L.; Edlund, M.; Lindstrom, S.; Van de Vreken, W.; McGowan, D.; Tahri, A.; Hu, L.; Lenz, O.; Delouvroy, F.; Van Dooren, M.; Kindermans, N.; Surleraux, D.; Wigerinck, P.; Rosenquist, A; Samuelsson, B; Simmen, K.; Raboisson, P. Discovery of novel, potent and bioavailable proline-urea based macrocyclic HCV NS3/4A protease inhibitors. Bioorg. Med. Chem. Lett., 2008, 18, 6189-6193.
104. Atazanavir is an aza-peptide HIV protease inhibitor. For a recent review, see: Perez-Elias, M. J. Atazanavir: simplicity and convenience in different scenarios. Expert Opin. Pharmacother., 2007, 8, 689-700.
105. Randolph, J. T.; Zhang, X.; Huang, P. P.; Klein, L. L.; Kurtz, K. A.; Konstantinidis, A. K.; He, W.; Kati, W. M.; Kempf, D. J. Synthesis, antiviral activity, and conformational studies of a P3 aza-peptide analog of a potent macrocyclic tripeptide HCV protease inhibitor. Bioorg. Med. Chem. Lett., 2008, 18, 2745-2750.
106. Back, M.; Johansson, P.-O.; Wangsell, F.; Thorstensson, F.; Kvarnstrom, I.; Ayesa, S.; Wahling, H.; Pelcman, M.; Jansson, K.; Lindstrom, S.; Wallberg, H.; Classon, B.; Rydergard, C.; Vrang, L.; Hamelink, E.; Hallberg, A.; Rosenquist, A.; Samuelsson, B. Novel potentmacrocyclic inhibitors of the hepatitis C virus NS3 protease: use of cyclopentane and cyclopentene P2-motifs. Bioorg. Med. Chem., 2007, 15, 7184-7202.
107. Manns, M. P.; Reesink, H. W.; Moreno, C.; Berg, T.; Benhamou, Y.; Horsmans, Y. J.; Dusheiko, G. M.; Flisiak, R.; Meyvisch, P.; Lenz, O.; Simmen, K.; Verloes, R. Safety and antiviral activity of TMC435350 in treatment-naive genotype 1 HCV-infected patients. Hepatology, 2008, 48, LB8, 1023A.
108. Sheng, X. C.; Pyun, H.-J.; Chaudhary, K.; Wang, J.; Doerffler, E.; Fleury, M.; McMurtrie, D.; Chen, X.; Delaney IV, W. E.; Kim, C. U. Discovery of novel phosphonate derivatives as hepatitis C virus NS3 protease inhibitors. Bioorg. Med. Chem. Lett., 2009, 19, 3453-3457.
109. Venkatraman, S.; Velazquez, F.; Wu, W.; Blackman, M.; Chen, K. X.; Bogen, S.; Nair, L.; Tong, X.; Chase, R.; Hart, A.; Agrawal, S.; Pichardo, J.; Prongay, A.; Cheng, K.-C.; Girijavallabhan, V.; Pi-winski, J.; Shih, N.-Y.; Njoroge, F. G. Discovery and structure-activity relationship of P1-P3 ketoamide derived macrocyclic inhibitors of hepatitis C virus NS3 protease. J. Med. Chem., 2009, 52, 336-346.
110. Velazquez, F.; Venkatraman, S.; Blackman, M.; Pinto, P.; Bogen, S.; Sannigrahi, M.; Chen, K.; Pichardo, J.; Hart, A.; Tong, X.; Giri-javallabhan, V.; Njoroge, F. G. Design, synthesis, and evaluation of oxygen-containing macrocyclic peptidomimetics as inhibitors of HCV NS3 protease. J. Med. Chem., 2009, 52, 700-708.
111. Velazquez, F.; Venkatraman, S.; Wu, W.; Blackman, M.; Prongay, A.; Girijavallabhan, V.; Shih, N.-Y.; Njoroge, F. G. Application of ring-closing metathesis for the synthesis of macrocyclic pepti-domimetics as inhibitors of HCV NS3 protease. Org. Lett., 2007, 9, 3061-3064.
112. McCauley, J. A.; Rudd, M. T.; Nguyen, K. T.; McIntyre, C. J.; Romano, J. J.; Bush, K. J.; Varga, S. L.; Ross, C. W., III; Carroll, S. S.; DiMuzio, J.; Stahlhut, M. W.; Olsen, D. B.; Lyle, T. A.; Vacca, J. P.; Liverton, N. J. Bismacrocyclic inhibitors of hepatitis C NS3/4A protease. Angew. Chem., Int. Ed., 2008, 47, 9104-9107.
113. Koev, G.; Kati, W. The emerging field of HCV drug resistance. Expert Opin. Investig. Drugs, 2008, 17, 303-319.